SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

FRASSOLDATI, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.133
EU - Europa 1.255
AS - Asia 1.218
SA - Sud America 37
OC - Oceania 10
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.658
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.111
CN - Cina 525
SG - Singapore 361
IT - Italia 338
TR - Turchia 176
DE - Germania 174
PL - Polonia 168
UA - Ucraina 144
GB - Regno Unito 143
SE - Svezia 119
ID - Indonesia 82
FI - Finlandia 47
BE - Belgio 39
BR - Brasile 33
VN - Vietnam 28
CA - Canada 17
CZ - Repubblica Ceca 14
NL - Olanda 14
FR - Francia 12
IN - India 12
AU - Australia 9
JP - Giappone 9
IE - Irlanda 8
IR - Iran 6
LT - Lituania 6
ES - Italia 5
MX - Messico 5
AT - Austria 4
HK - Hong Kong 4
RO - Romania 4
CH - Svizzera 3
CL - Cile 3
AL - Albania 2
IL - Israele 2
KR - Corea 2
NO - Norvegia 2
RU - Federazione Russa 2
BD - Bangladesh 1
EG - Egitto 1
HU - Ungheria 1
IM - Isola di Man 1
IQ - Iraq 1
JO - Giordania 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MA - Marocco 1
MD - Moldavia 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZA - Sudafrica 1
Totale 8.658
Salva come PNG Salva come JPEG
Città #
Fairfield 868
Woodbridge 751
Houston 456
Ashburn 418
Chandler 416
Santa Clara 369
Seattle 348
Wilmington 327
Ann Arbor 321
Cambridge 304
Singapore 268
Jacksonville 253
Warsaw 168
Izmir 158
Beijing 120
Princeton 104
Nanjing 96
Ferrara 80
Jakarta 80
New York 53
Boardman 52
San Diego 51
Shanghai 49
Milan 43
Brussels 39
Helsinki 36
Nanchang 36
Falls Church 35
Los Angeles 33
Dearborn 32
Hebei 32
London 28
Dong Ket 25
Shenyang 25
Redwood City 23
Tianjin 20
Des Moines 18
Norwalk 18
Changsha 17
Bremen 16
Bologna 15
Munich 14
Guangzhou 13
Jiaxing 13
Kunming 11
Mountain View 11
Addison 10
Toronto 10
Brno 9
Falkenstein 9
Kilburn 9
Redmond 9
Verona 8
Dublin 7
Washington 7
Chicago 6
Edinburgh 6
Ferrara di Monte Baldo 6
Hefei 6
Orange 6
Ottawa 6
San Mateo 6
Tokyo 6
Jinan 5
La Jolla 5
Tappahannock 5
Fords 4
Frankfurt am Main 4
Fuzhou 4
Hangzhou 4
Hong Kong 4
Hounslow 4
Philadelphia 4
Rome 4
Sant'Elpidio a Mare 4
Vienna 4
Zhengzhou 4
Changchun 3
Chiswick 3
Dalian 3
High Point 3
Indiana 3
Lappeenranta 3
Las Vegas 3
Mexico 3
Monmouth Junction 3
Ningbo 3
North Bergen 3
Padova 3
Parma 3
Pittsburgh 3
Saint Louis 3
São Paulo 3
Wandsworth 3
Agrigento 2
Ancona 2
Baldissero Torinese 2
Belo Horizonte 2
Bonate Sopra 2
Brescia 2
Totale 6.911
Salva come PNG Salva come JPEG
Nome #
Absolute quantification of cell-free microRNAs in cancer patients 192
Diagnostic and prognostic microRNAs in the serum of breast cancer patients measured by droplet digital PCR 174
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 173
High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy 171
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 170
miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model 155
Reversibility of Left Ventricle Longitudinal Strain Alterations Induced by Adjuvant Therapy in Early Breast Cancer Patients 151
Gastrointestinal stromal tumors and other malignancies: A case series 149
Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study 146
Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study 141
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: Implications for personalised treatment 133
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 130
Preoperative chemotherapy plus lapatinib or trastuzumab or both in HER2-positive operable breast cancer (CHERLOB trial) 127
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy 124
Current views on anthracycline cardiotoxicity 118
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion 113
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 113
Synchronous papillary carcinoma and hemangiopericytoma with lung metastases 112
Ovarian endometrioid adenocarcinoma with a yolk sac tumor component in a postmenopausal woman: Case report and review of the literature 109
The management of skin toxicity during cetuximab treatment in advanced colorectal cancer: How much does it cost? A retrospecive economic assessment from a single-center experience 107
HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights 106
Double-blind, placebo-controlled, multicenter, randomized, phase IIB neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 104
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 104
Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study 103
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 103
Trends in net survival from liver cancer in six European Latin countries: results from the SUDCAN population-based study 102
Risk of second cancer in patients with hairy cell leukemia: long-term follow-up 102
Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study 101
The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients 100
Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer 98
Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients 97
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 97
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab 97
Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: A survey among Italian oncologists 96
HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results 96
Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: A double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB) 96
Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable? 95
Primary systemic therapy in operable breast cancer: Clinical data and biological fall-out 95
Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective 94
Predictive value of biologic parameters for primary chemotherapy in operable breast cancer 94
Magnetic resonance imaging and ultrasonography in predicting infiltrating residual disease after preoperative chemotherapy in stage II-III breast cancer 93
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results 93
Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy 93
Patient and Health Care Professional Perspectives: A Case Study of the Lung Cancer Integrated Care Pathway 92
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials 91
Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial 91
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 91
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: Results of the PerELISA neoadjuvant study 91
Primary systemic therapy for operable breast cancer: A review of clinical trials and perspectives 90
Il protocollo Diagnostico-Terapeutico e Assistenziale per il carcinoma mammario della Regione Emilia-Romagna. I edizione 89
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278) 88
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting 88
Gene expression profiling in breast cancer: A clinical perspective 87
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer 85
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 85
The role of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) in patients with breast cancer recurrence: a comparison to conventional imaging (CI) techniques and clinical impact on patient management 84
The role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in suspected recovery of breast cancer disease: comparison with Radiological Imaging and impact on patient management 83
Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? 82
The promher study: An observational Italian study on adjuvant therapy for her2-positive, pT1a-b pN0 breast cancer 80
Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM) 80
Changes of biological features in breast cancer cells determined by primary chemotherapy 78
Estrogen receptor mutation: a new strategy to overcome endocrine resistance 78
null 77
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 75
Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: Extending endocrine sensitivity 70
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 68
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 66
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 66
Pattern of distant recurrence according to the molecular subtypes identified by immunohistochemistry in women with early breast cancer 65
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study 65
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 64
"Triple positive" early breast cancer: An observational multicenter retrospective analysis of outcome 62
Clinical-diagnostic relevance of breast “incidentaloma” detected during 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography: Correlation with radiological imaging and histopathology 61
Pulmonary strongyloidiasis mimicking cancer symptoms: A case of hyperinfection in a patient with metastatic lung cancer 60
Observational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study 58
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 58
Tumor infiltrating lymphocytes in triple negative breast cancer and correlations with prognosis 56
Immune Checkpoint Inhibitor Nivolumab and Radiotherapy in Pretreated Lung Cancer Patients: Efficacy and Safety of Combination 56
Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib 56
Gli standard oncologici nel Percorso Diagnostico Terapeutico Assistenziale del paziente con carcinoma del colon: Dati del biennio 2009-2010 presso l'UO di Oncologia Clinica dell'AOU di Ferrara 55
Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer 55
Italian cohort of the nivolumab EAP in squamous NSCLC: Efficacy and safety in patients with CNS metastases 54
Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities? 53
The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer 51
The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma 48
Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways 47
Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke 45
18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? 43
Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives 43
Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study 42
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 42
Erratum: miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 39
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 39
How to fish a good micro-marker out from a worthless lake: The case of cell-free miR-181a-5p and breast cancer 38
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 38
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study 37
miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models 34
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program 31
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study 28
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 28
Totale 8.673
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.621
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.621
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.091 0 0 0 0 0 241 208 167 185 147 84 59
2020/20211.454 64 86 63 133 71 154 56 165 104 254 167 137
2021/2022844 33 48 53 22 26 109 76 42 57 109 48 221
2022/20231.024 116 59 60 112 134 133 49 124 119 11 71 36
2023/2024582 55 70 27 19 42 88 25 52 12 15 19 158
2024/20251.083 70 76 229 119 345 244 0 0 0 0 0 0
Totale 8.924